Physician profile
Michael D Kwan
NPI 1942267802
$15,599.15
in general payments reported to CMS, 2019-2025
39 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,982 · 2020: $1,190 · 2021: $1,665 · 2022: $2,762 · 2023: $2,714 · 2024: $3,143 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,000.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,391.37 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Coronary |
| Abiomed | $2,647.92 | 2019-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $1,526.45 | 2019-2024 | Uptravi, Opsumit |
| Cvrx, INC. | $931.99 | 2020-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $552.44 | 2019-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $490.53 | 2021-2024 | Optimizer, Optimizer |
| Medtronic Vascular, INC. | $431.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $372.71 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $357.17 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $313.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $291.39 | 2021-2025 | Verquvo, Winrevair |
| United Therapeutics Corporation | $289.06 | 2019-2025 | Tyvaso |
| Inari Medical, INC. | $182.28 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Portola Pharmaceuticals, LLC | $166.28 | 2019-2020 | |
| Boston Scientific Corporation | $137.07 | 2025 | Cds - Other, Cds - Mct/Cem Monitoring |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.